Transcriptomics

Dataset Information

244

IGR_BLADDER_GE_STUDY_JA


ABSTRACT: Background: Although histology is the corner stone for decision analysis in bladder cancer, it still needs refinement and new tools to better identify tumours with the highest risk of progression or recurrence. Objective: We designed a prospective study to evaluate whether microarray analysis could find a molecular signature for pathologic staging and/or grading. Design, setting and participants: Prospective multicentric study conducted from September 2007 to May 2008 (108 bladder tumours (45 pTa, 35 pT1 and 28> pT1)). Microarray analysis was performed with Agilent Technologies Human Whole Genome 4 x 44K oligonucleotide microarrays and used a method of dual color type versus a reference consists of a pool of tumours. From the lists of genes provided by the BrB Class Comparison analyses, we validated the microarray results of 38 selected differentially expressed genes by RT-QPCR in another bladder tumour cohort (n = 95). Results: The cluster superficial vs invasive stage properly classified 92.9% of invasive stages and 66.3% of superficial stages. Among the superficial tumours, the cluster analysis showed that pT1b tumours were closer to invasive stages than pT1a tumours. We also found molecular differences between low and high-grade superficial tumours. However these differences were less caricatural than the one observed for staging.Conclusions: We confirm that the histopathological classification into subgroups pTa, pT1a and pT1b may have a translation in a molecular signature with a continuous progression of deregulation (overexpression or repression of these genes) from superficial (pTa) to more invasive (pT1a then b stage).

ORGANISM(S): Homo sapiens  

DISEASE(S): Superficial Bladder Tumour,Bladder Tumour,Invasive Bladder Tumour

SUBMITTER: Philippe DESSEN  

PROVIDER: E-MTAB-993 | ArrayExpress | 2013-08-13

REPOSITORIES: ArrayExpress

altmetric image

Publications


OBJECTIVE: To try and identify a molecular signature for pathological staging and/or grading. through microarray analysis. PATIENTS AND METHODS: We performed a prospective multicentre study between September 2007 and May 2008 that included 108 bladder tumours (45 pTa, 35 pT1 and 28>pT1). Microarray analysis was performed using Agilent Technologies Human Whole Genome 4 × 44K oligonucleotide microarrays (Agilent, Santa Clara, CA, USA). A 'dual colour' method was used vs a reference pool of tumours  ...[more]

Similar Datasets

2010-05-01 | E-TABM-746 | ArrayExpress
2013-06-30 | E-MTAB-1221 | ArrayExpress
2010-12-31 | E-TABM-873 | ArrayExpress
2013-08-08 | E-MTAB-897 | ArrayExpress
2012-06-11 | E-TABM-1215 | ArrayExpress
2013-06-24 | E-MTAB-1452 | ArrayExpress
2018-11-07 | E-MTAB-4869 | ArrayExpress
2009-03-12 | E-TABM-611 | ArrayExpress
2010-03-18 | E-TABM-899 | ArrayExpress
2010-07-31 | E-TABM-760 | ArrayExpress